Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Long-Term Investments
Apontis Pharma AG
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Long-Term Investments
€801.2k
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Long-Term Investments
$91.7m
|
CAGR 3-Years
125%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Long-Term Investments
€3.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Merck KGaA
XETRA:MRK
|
Long-Term Investments
€1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
29%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Long-Term Investments
€84.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Long-Term Investments
€1.3m
|
CAGR 3-Years
175%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Long-Term Investments?
Long-Term Investments
801.2k
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Long-Term Investments amounts to 801.2k EUR.
What is Apontis Pharma AG's Long-Term Investments growth rate?
Long-Term Investments CAGR 3Y
8%
Over the last year, the Long-Term Investments growth was 8%. The average annual Long-Term Investments growth rates for Apontis Pharma AG have been 8% over the past three years .
You don't have any saved screeners yet